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ABSTRACT
The artificial pancreas system or an automated
insulin dosing system has been the ‘holy grail’
for patients with type 1 diabetes and their
caregivers who have over the years wanted to
‘close the loop’ between monitoring of glucose
and delivery of insulin. The launch of the
Medtronic MiniMed 670G system in 2017 and
the subsequent release of the Tandem t:slim
with Control-IQ system, the DANA RS pump
compatible-CamAPS FX app and the more
recent announcement of the Medtronic Mini-
Med 780G system have come as answers to their
prayers. However, in the time taken to develop
and launch these commercial systems, creative
and ebullient parents of young patients with
type 1 diabetes, along with other patients,
technologists and healthcare professionals have
developed mathematical models as software
solutions to determine insulin delivery that in
conjunction with compatible hardware have
helped ‘close the loop’. Under an umbrella
movement #WeAreNotWaiting, they have, as a
community, refined and disseminated tech-
nologies that are open source and ubiquitously
available as do-it-yourself (DIY) closed-loop
systems or DIY artificial pancreas systems (APS).
There are presently three systems—OpenAPS,
AndroidAPS and Loop. We present perspectives
of two patients, parent of a patient, and their
healthcare providers; the users spanning an age
spectrum most likely to use this technology—a
child, an adolescent in transitional care and a
31-yr old adult patient, highlighting how loop-
ing has helped them self-manage diabetes
within the routine of their lives and the chal-
lenges they faced.
Keywords: Artificial pancreas systems; Type 1
diabetes; Continuous glucose monitoring; Do-
it-yourself (DIY); Insulin pump therapy;
Hypoglycaemia; Time-in-range
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Key Summary Points
In this commentary, two adult patients
and the caregiver of a patient, with type 1
diabetes share their experiences on DIY
artificial pancreas systems. Their
healthcare providers
provide clinical perspectives.
The users’ quality of life and ability to self-
mange diabetes have been enhanced by
this open source technology. By adopting
DIY systems, they have joined a
#WeAreNotWaiting community that is
willing to innovate, experiment and
promote technology, modelled on the
function of a healthy human pancreas.
Further research would help UK regulatory
bodies develop the guidance, for
healthcare professionals, to support DIY
APS users.
PERSPECTIVESOF TWO ADULT
USERS AND PARENT OF A USER
Nicola’s Story
I am a 31-year veterinary surgeon living with
type 1 diabetes since 2008. With a scientific
background I have always strived for the ‘‘per-
fect’’ control of my condition, but this has
always come with a huge and unrelenting
mental daily burden. Around 18 months ago I
stumbled across the concept of looping online
and began to learn about this automated insulin
delivery system. I was excited at the possibil-
ity of having some of my disease burden allevi-
ated. Loop utilises inputted data and glucose
readings to predict future blood glucose level
and will adjust basal rates up or down accord-
ingly. The algorithm alters this decision every
5 min and the predicted trend of your blood
glucose is shown, alongside active insulin,
insulin delivery and active carbohydrates. This
information is presented on the Loop home
screen (Fig. 1). It is recommended to set dura-
tion of insulin action (DIA) to 6 h with Loop,
longer than that recommended for traditional
pumping to prevent insulin stacking.
During the transition to Loop one of the
challenges was learning to understand and trust
the different recommendations given for bolu-
ses which did not always correlate with what I
would have calculated using traditional pump
therapy. It took time to get used to the concept
that bolus and basal are more interchangeable
with Loop, so an increased basal after a meal
needs to be considered as an extended bolus
would on traditional pump therapy. Switching
from using a Personal Diabetes Manager (PDM)
to my phone and using my Apple watch
Fig. 1 Loop app home screen on an iPhone showing
active carbohydrates, insulin delivery, active insulin
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allowed me to more discretely manage my
condition but this came with the practical
challenge of ensuring I always had enough
phone battery power or a charger with me. I also
had to ensure I always had my RileyLink with
me, but soon got used to this. At home it can be
in another room and still communicate effec-
tively but I try to keep it with me as much as
possible.
I set up a Nightscout profile which collates
all of my continuous glucose monitor (CGM),
insulin delivery and carbohydrate information
to produce reports which can then be viewed by
healthcare professionals.
Loop utilises ‘‘carbohydrate absorption time’’
rather than extended boluses. Carbohydrate
absorption is tracked over time and basal rates
are adjusted accordingly after the initial upfront
bolus. A progress bar shows carbohydrate
absorption, helping the user to learn different
foods’ absorption profiles so more educated
guesses can be made in future for the same
meal, minimising the risk of hypoglycaemia.
High fat meals such as pizza are handled better
with Loop than I managed with conventional
pumping and whilst I cannot say that Loop
stops any blood glucose rises, it has reduced my
time out of range and the height of any spikes,
reducing the requirement for repeated correc-
tion doses. I still find that pre-bolusing is the
most successful way of preventing glucose
spikes after meals; there is also a user preset
‘‘pre-meal’’ setting which can be enacted for up
to 1 h before eating, allowing more insulin on
board when the meal is digested.
Exercise-induced hypos are less common for
me on Loop, as the algorithm anticipates any
impending low blood glucose and reduces the
basal rate. Carbohydrate portions for correction
of hypoglycaemia are lower, for example I now
require 1–2 dextrose tablets instead of 3 to
promptly correct hypoglycaemia and avoid
post-correction hyperglycaemic excursions.
Overrides and temporary targets are a valuable
feature to deal with scenarios where insulin
requirements differ from baseline. I use these
settings commonly for work, exercise and post
exercise to combat hypoglycaemia (Fig. 2).
There are some downsides to the Loop sys-
tem; although for me, these are far outweighed
by the positives. It requires a significant ongo-
ing financial input and a substantial time to
read and understand the algorithm and to set
up the system. Being somewhat technologically
savvy is also a bonus, although the instructions
for setting up the system are comprehensive
and there is a community of people available
online to help. However, new users should be
under no illusion that you simply ‘‘plug in and
go’’—Loop needs accurate settings such as car-
bohydrate ratios, insulin sensitivity and target
glucose ranges to work safely and effectively.
More practical pitfalls with looping relate to the
CGM used; I use the Dexcom G6 which I have
found to be very reliable and accurate in its
readings; however, on the infrequent occasion
that there is a sensor error, the lack of CGM data
Fig. 2 Temporary preset overrides for different situations
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means that Loop cannot function. Insulin
delivery will continue as the OmniPod will
revert back to its preset basal rate but if there are
any carbohydrates on board then Loop cannot
make its basal adjustments to compensate for
this.
After just under 12 months of looping, I
found that my initial monetary, effort and time
investment paid off as improvement in my
overall control and quality of life.
My HbA1c has reduced from 6.5% to 5.5%
and my time-in-range (TIR) is 76% for my per-
sonalized target range of 3.9–7.8 mmol/l
(90–95% for the standard target range of 3.9–-
10 mmol/l) with less post-meal hyperglycaemia
(Fig. 3). Improvements in my quality of life
include an undisturbed overnight sleep, less
time spent making decisions regarding insulin
management and improved confidence when
exercising.
Loop technology is undergoing constant
development, with input and suggestions from
users, researchers and healthcare specialists. I
am excited to see where this project goes next
and cannot express my gratitude to those
involved in its creation/maintenance and to my
healthcare team for supporting me in my deci-
sion to use a combination of licensed and
unlicensed products in an off-label manner.
Cormac’s Story
I was diagnosed with type 1 diabetes in January
2018, aged 16 and began treatment with a
multiple injection regimen (MDI) and glucose
monitoring with an Accu-Chek meter. After
approximately 8 months of maintaining good
control and an HbA1c of below 50 mmol/mol, I
began to find it more difficult to keep within a
healthy range. I left one clinic appointment in
tears, feeling like I’d failed with an HbA1c result
of above 70. Some days I didn’t want to see the
blood glucose levels so I didn’t carry out many
finger prick tests; other days I checked obses-
sively with over 20 checks being recorded on
my meter. These feelings affected my dietary
habits and, on some days, I refused to eat as I
felt eating wasn’t worth the bother of doing the
check or the injection. After sharing these
thoughts with my diabetes specialist nurse
(DSN), I was offered the FreeStyle Libre. This felt
like a positive step in my management as it
would alleviate some of my finger prick checks.
However, decisions to scan, when to scan and
then to decide on the correct bolus were ever-
present. It was also frustrating not knowing
what was happening between checks and not
knowing what was going to happen to my glu-
cose levels in the near future.
I have a general interest in technology and
my research led me to an article which descri-
bed the MiaoMiao, a device that was capable of
transforming the FreeStyle Libre into a CGM. I
was fortunate that my parents agreed to pur-
chase a MiaoMiao for me in May 2019 which,
for the first time, allowed constant monitoring
of glucose levels. In addition, using Nightscout,
I was able to see predicted glucose levels and
share my data with my parents and my DSN. My
parents are conscientious supporters in my
management of diabetes and sharing the data
with them meant that our conversations
Fig. 3 A 90-day average before (left) and after (right) Nicola started using looping shows improvements in time-in-range
(TIR) from 48% to 76%, in the average glucose and standard deviation from 7.8 ± 2.8 to 6.1 ± 1.9 mmol/l
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weren’t solely about blood glucose levels any-
more! Nightscout also predicts HbA1c values,
meaning that I could attend clinic appoint-
ments with some idea of how the conversation
with the consultant was going to go.
My research also led me to discover DIY APS
(looping) with the potential to connect my
FreeStyle Libre/MiaoMiao combination to a
suitable insulin pump via a device called a
RileyLink. I was supported in my decision to
move from MDI to the OmniPod in June 2019. I
chose the OmniPod for its compatibility with
the DIY APS system. I spoke at length to my
DSN about my intention to try DIY APS; she was
supportive of this patient-led management of
my diabetes, whilst also ensuring that I was
aware that looping is not currently regulated.
After I had used the OmniPod for approxi-
mately 4 weeks with its PDM, my parents agreed
to purchase a RileyLink in July 2019. Whilst
waiting for its delivery from USA I thoroughly
read through Loop docs online, joined looping,
AndroidAPS and OpenAPS groups on social
media and began to build the iOS Loop app. I
found the creation of the app fairly straight-
forward, following the instructions in the Loop
docs. The connection between the Riley Link
and the OmniPod was almost identical to the
process of connecting the OmniPod to the
PDM. I initially used the Loop app in its open
loop mode which requires user verification and
confirmation of all decisions made by the app. I
found that all the suggested decisions were
sensible, much more frequently than I would
have made independently (every 5 min) and
put a greater weighting on the predicted glucose
levels than I would have previously done. Fig-
ure 4 shows how I loop with the different
components.
I felt confident in the open loop and the
decisions that were being suggested, so, on the
second evening, I decided to close the loop to
see what would happen. It was not uncommon
for me to experience nocturnal hypos, but
overnight the glucose levels remained stable.
Since then I have been using the closed-loop
configuration with consistently good results. I
have seen my HbA1c level drop to
42 mmol/mol with a reduction in the number
of hypo and hyper episodes and around 80% of
my time in range (Fig. 5).
In November 2019 I attended a looping
conference in London where members of the
looping community shared advice and
Fig. 4 Diagram describing how different components of Cormac’s APS communicate to close the loop
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experiences. I was advised to use the Loop with
caution; if in doubt, to open the Loop and take
back control. I have not experienced any soft-
ware issues since looping but do experience
occasional highs which are corrected by the
Loop without subsequent overcorrection lows.
My hypos are now less frequent and less severe.
Looping has had a positive effect on my mental
health. I am grateful that my medical team
understand and support my decision to under-
take this method of diabetes management. I
now perceive diabetes to be less of a burden and
less time consuming in my day to day life. The
impact of having diabetes on my academic
career is reduced as I now spend less time
extracting myself from lessons and I am confi-
dent that my Loop is automating insulin deliv-
ery correctly.
Harry’s Story
My name is Claire, and my son Harry was
diagnosed with type 1 diabetes in April 2013
just 2 weeks after his third birthday. Harry used
MDI as a way of treatment until December 2015
when he switched to the Animas Vibe pump.
In November 2015 we were given the
opportunity to trial the Dexcom G4 CGM. This
was a game changer for us. It was as though the
mask I had been wearing since Harry’s diagnosis
had finally been lifted. I suddenly felt able to
care for my child in a way I never thought I
could. From this day forward, I made it my
mission to understand and try to keep up with
all the latest diabetes technology available. I
needed my boy to live his best life.
I joined some new Facebook groups, which
was the start of our next exciting diabetic jour-
ney. Reading what other parents do is a great
way of learning new tricks and finding out
about new technology that is available. I came
across the word ‘‘Nightscout’’ over and over so
decided to find out what exactly this was and
how I could have it!
Nightscout, or CGM in the cloud, was
developed by parents of children with type 1
diabetes and is an open-source DIY project that
allows real-time access to CGM data via your
own personal website and it completely chan-
ged our lives. It gave us freedom that we simply
hadn’t had since before diagnosis, freedom to
sleep easier, to relax when my boy was in
another room or playing in the garden, to allow
him to be a child and not have to be monitored
so closely anymore; it gave me my first taste of
remote monitoring, and I loved it!
Fast forward to late 2018, a close friend of
mine (someone I met online whilst setting up
Nightscout) had set up, and been using flaw-
lessly, a system called Android APS with her
daughter. Something I knew very little about, a
system I believed would be too difficult for me
to set up, so I put off reading too much about its
brilliance, as to not get my hopes up. However,
as always curiosity got the better of me, and I
asked for help. I couldn’t let my fear of failure
stop me trying.
February 2019, during the half-term school
break, I finally set up my very own DIY APS for
Harry. Over a year later and I am shocked how
amazing and clever this system is.
Currently the system we use includes Dex-
com G6 CGM and an Accu-Chek Spirit Combo
insulin pump, which Android APS controls via
Fig. 5 Cormac’s 30-day glucose distribution data pre (left)
and post (right) looping shows reduction in hypoglycaemia
from 13.3% to 6.7%, increase in time-in-range (TIR) from
66.9% to 79.7%, improvement in glycaemic variability
index (GVI) from 1.43 to 1.39 and in patient glycaemic
status (PGS) from 62.01 to 35.27
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Bluetooth (Fig. 6). To see it in action still has me
amazed.
Originally, we set up using a Samsung J4?
which worked brilliantly until we switched
from Dexcom G5 to G6 in December 2019,
when it was then no longer compatible, so we
purchased the Xiaomi Mi A2 Lite which has
been working flawlessly since. Harry also wears
a TicWatch Pro smartwatch, which he can also
bolus by entering the carbs and it will calculate
the insulin needed.
Fig. 6 Top left, bottom left and right—Harry having fun
camping. Top right—Harry’s AndroidAPS home screen;
components of Harry’s APS system: 1, Accu-Chek Spirit
Combo Insulin pump; 2, Dexcom G6; 3, Android
smartphone Xiaomi Mi A2 lite; 4, TicWatch Pro
Smartwatch
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Harry is 10 years old now and becoming
more independent so this is really what pushed
me to get this set up, as I’m sure before long he
will want to take the reins off me completely
and I wanted him to be fully prepared and have
the best system to work with, and you can’t get
much better than this.
Before APS was in our lives, I struggled to
sleep. I micromanaged Harry’s diabetes to the
best of my ability 24/7 and was quite hard on
myself when things didn’t quite go to plan; and
let’s face it, diabetes often doesn’t play fair!
Harry’s HbA1c has never been of concern and
has always been in range. This was never my
incentive; bringing back some normality into
our lives is what I craved, what we dreamed of.
Android APS has allowed me to take a step back;
it has allowed me to take a deep breath and see
that my son can survive, and survive well,
without my constant and often annoying,
interference.
The biggest change for me though is Harry’s
confidence. He says he feels more like his
friends now; he is happier, as though it has
taken away some of the burden for him. In
school he rarely has to give diabetes a second
thought anymore. He knows the system he has
is constantly working at keeping him safe and
he has learned to trust it. He understands how
to respond to the alarms, and knows that if he
does this, he feels better and so there are less
interruptions on his day. He isn’t able to give
himself correction insulin yet, without super-
vision, but he knows I am always keeping an eye
on his glucose readings from wherever I am, and
he can see when I send a text to give him a bolus
so he can relax again knowing that things are
under control. The remote bolusing via text
message is brilliant; it means I never have to
interrupt his learning or, more importantly, his
play time, just to give insulin. Which when
you’re 10 is kind of a big deal.
Even though APS is taking the lead, I still feel
completely in control; I am the one calling the
shots. I can also turn it off via a press of a but-
ton, which I have only done when encounter-
ing faulty sensors, but it’s good to know the
option is there should you need it. APS isn’t a
quick fix; we still get highs and lows, but just
not as severe or as often as we did without it.
Our hypo treatment has halved since we have
been looping which speaks volumes in itself,
whilst still keeping an HbA1c anyone should be
proud of. Diabetes is tough, but having an APS
to help makes life that little bit easier to
manage.
PHYSICIAN PERSPECTIVE
The Artificial Pancreas System (APS)
An APS is a system consisting of an insulin
pump, a CGM device and a central micropro-
cessor integrating the data to provide auto-
mated insulin delivery (AID) based upon
interstitial fluid glucose readings and other
variables. It is a closed-loop system hybridised to
integrate manual data such as carbohydrate
intake, glucose targets and other profiles.
A DIY APS or DIY hybrid closed-loop system
(known as looping) is created by the user using
source code freely available from software
development platforms such as GitHub. There
are currently three main systems in DIY looping:
OpenAPS, Android APS and Loop (Table 1). The
current three commercially available APS sys-
tems: the Medtronic MiniMed 670G, the Tan-
dem t:slim with Control-IQ and the DANA RS
pump compatible-CamAPS FX app, lack the
customization and flexibility afforded by DIY
loop systems. The MiniMed 780G system se-
cured the CE marking in June 2020 and is yet to
be commercially launched; compared to the
670G, it has added features, prominent of which
are, the ability to adjust target setting to as low
as 5.5mmol/L and Bluetooth connectivity with
compatible iOS and Android systems.
DIY looping was driven by the desire of
people living with diabetes (#WeAreNotWait-
ing) to devise a system mimicking the human
pancreas to reduce the burden of daily diabetes
management. The idea that an algorithm could
be designed to predict glucose trends and
shared via the cloud was conceived by John
Costik in 2013 and developed as the Nightscout
project [1]. Dana Lewis, after successfully trial-
ing this concept with her CGM, worked with
John Costik to further refine the algorithm.
Later they worked with Ben West and in 2014
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devised a system that allowed them to control a
pump in conjunction with the CGM and the
predictive algorithm to ‘close the loop’—
launching the OpenAPS movement [1].
Their prototype DIY rig consisted of a
microprocessor holding the algorithm, a radio
stick for communication, a pump and CGM. In
Table 1, we have detailed the different
components and software interfaces required
for the current three types of systems.
The first algorithm released, oref0 (OpenAPS
Reference Design Zero), has evolved over time
with features to limit hyperglycaemia whilst
minimising hypoglycaemia. The newer oref1
algorithm instructs the pump to give small ‘su-
permicroboluses’ in response to post-prandial
rises in the blood glucose.
Table 1 The three DIY APS systems and associated technology
Systems OpenAPS AndroidAPS Loop
Designers Dana Lewis, Scott Leibrand,
Ben West
Milos Kozak, Adrian Tappe Nate Racklyeft, Peter
Schwamb
Pumps Old Medtronic (versions
before 2011)





CGM systems Dexcom G4, G5, G6,
Medtronic Enlite or MiniMed
Paradigm REAL-time Revel, xDrip?
FreeStyle Libre with MiaoMiao
Synchronizes with Nightscout
Dexcom G4, G5, G6,
Eversense, Medtronic
Guardian or Enlite, xDrip?
FreeStyle Libre with MiaoMiao
Can synchronize with
Nightscout









Small computer (e.g. Intel
Edison or Raspberry Pi) and a
radioboard/stick
(Explorer Board for Edison
or Explorer HAT for Pi)
xDrip Wireless Bridge
(Wixel) for xDrip users
Android phone, xDrip Wireless
Bridge (Wixel) for xDrip
users
iPhone, RileyLink
- 916 MHz for
Medtronic
- 433 MHz for
OmniPod Eros
User interface devices Pebble smart watch
Android phone
iPhone






Operating system Android iOS
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Currently OpenAPS and AndroidAPS imple-
ment the oref0 algorithm, whereas Loop uses a
different algorithmwherein insulin is adjusted on
the basis of future predicted glucose levels. Cor-
mac’s APS in Fig. 4 exemplifies how the different
components of DIY system work in tandem as an
automated loop. Cormac uses a FreeStyle Libre
with MiaoMiao whereas Nicola and Harry use a
DexcomG6 for CGM; Cormac and Nicola use the
Spike and Loop apps on their iPhones, have
RileyLinks as intermediate hardware, and use an
OmniPod patch pump for insulin delivery;
whereas Harry uses an Android-based Xiaomi Mi
A2 Lite phone as the microprocessor which
Table 2 Pros and cons of DIY APS as compared to traditional sensor-augmented pump therapy
Pros Cons
Reduction in number and severity of hypoglycaemic episodes Limited interoperability which means limited number of
pumps and CGM devices compatible for DIY systems.
However, the pool of different models that can ‘loop’ is
gradually expanding
Improved glycaemic stability, reduced variability Financial costs for additional hardware not covered by
insurance
Improvement of time-in-range (TIR) Warranty will not cover accidental damage of the pump or
CGM, caused by use within an unlicensed system
Reduced cognitive burden, as less time spent thinking and
planning about diabetes. Less time spent on diabetes-
related activity, giving more time and cognitive space to
focus on other activities in life
Additional hardware components such as the RileyLink/
xDrip wireless bridge/radioboard/stick/minicomputer
along with the battery and cables will have to carried along
in a separate case/purse or pocket, for the system to work.
However, the newer hybrid closed-loop systems have
Bluetooth connectivity, obviating the requirement of
intermediate hardware
Greater piece of mind and psychological reassurance to users
(and caregivers) regarding variables such as overnight
hypoglycaemia etc., leading to a better quality of sleep
Perceived and real technical barriers limiting individual
patient uptake
Improved overall quality of life Perceived and real lack of knowledge and understanding of
DIY systems among healthcare professionals
More responsive to an individual’s change in physiology Requires investment of time and effort to learn and set up
the system
Remote monitoring option by cloud-based system such as
Nightscout
Faster drain of pump and smartphone batteries
Supportive online DIY community Lack of randomised clinical trials to assess safety and efficacy
Regular software updates and refinement of algorithms that
are user-sensitive, and assist users to manage glycaemia
with minimal user input
Neither medically authorised nor regulated
Better flexibility and customization allowing communication
with portable devices e.g. Harry’s uses his smartwatch to
bolus from his pump
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communicates directly with his Accu-Chek Spirit
Combo insulin pump by Bluetooth. One can see
the importance of ‘interoperability’ of the differ-
ent devices in allowing patients to make an
informed and tested choice on the right compo-
nents that would work well for them.
What Is the Supporting Evidence?
Hybrid closed-loop systemshavebeen studied for
a number of years, expanding their role in type 1
diabetes as a means of achieving targeted gly-
caemic control whilst minimising the risk of
hypoglycaemia [2]. The first commercially
available closed-loop system was approved in
2016 by the US Food and Drug Administration
(FDA) for patients aged 15 years and older [3]. A
further landmark study established its safety and
efficacy across the age spectrum to patients as
young as 6 years [4]. However, evidence for
hybrid closed-loop systems using open-source
code is limited to observational studies, self-re-
ported patient outcomes, and anecdotal reports
with a conspicuous lack of robust clinical trials.
Observational data emphasises the usefulness of
this system in reducing hypoglycaemia, gly-
caemic variability, overnight controls and man-
agement burden with improvement in time-in-
range (TIR), HbA1c [5, 6] and sleep [5, 7]. A Twit-
ter analysis of posts from users and carers
demonstrated improvement in HbA1c, glucose
variability, diabetes burden andquality of life [7].
Further observational data from Korea [8] and
Italy [9] showed reduction of time in hypogly-
caemia andHbA1c. An analysis of CGMdata of 80
OpenAPS users showed improvement in TIR,
HbA1c, hypoglycaemia and glucose variability
[10]. It has been estimated that users can save up to
one day’s time per month spent making decisions
about diabetes management [11]. Table 2 sum-
marises the pros and cons of DIY APS systems as
compared to traditional sensor-augmented pump
therapy.
It is, however, important to appreciate that
most of the data is from highly motivated, tech-
savvy users and parents and thus subject to
significant selection bias. There is no objective
data from randomised clinical trials, on patients
with variable degree of control.
In addition, there are no formal studies
assessing risks of acute diabetic emergencies
such as hypoglycaemia, hyperglycaemia and
diabetic ketoacidosis (DKA), or long-term com-
plications and mortality.
There is a growing community of DIY users
with approximately 1896 individuals across the
world looping with various combinations of
hardware and software components [12], many
of whom are very active on social media. The
community works with a culture of ‘‘pay it for-
wards’’ whereby established users are encouraged
to support new members and aims to be self-
regulatory by discouraging unsafe practice [12].
Interoperability is the current mantra propa-
gated by the looping community to device
manufactures, encouraging them to develop
devices that have the ability to talk to each other,
using open communication protocols.
Tidepool, a non-profit organisation, is
working to build an FDA-regulated version of
Loop for iOS, to be available on the App store.
They are working with commercially available
pump manufactures in order to make Tidepool
Loop compatible with various products.
What Are the Ethical Concerns?
There is no current framework that governs the
accountability and responsibility on healthcare
provision to DIY users. The technology has not
been appraised or approved by regulatory bod-
ies such as the National Institute of Clinical
Excellence (NICE), FDA, and Medicine and
Healthcare products Regulatory Agency
(MHRA).
The Association of British Clinical Diabetol-
ogists (ABCD) encourages healthcare profes-
sionals (HCPs) to support their patient [13] but
advises that the HCP should not recommend
open source systems. The Juvenile Diabetes
Research Foundation (JDRF), whilst recognising
DIY technology as unregulated with potential
safety concerns, respects current DIY users and
appreciates that HCPs managing patients, who
choose to be DIY users, will require specific
training and enhanced indemnity to protect
them from medicolegal liability [14]. Technol-
ogy uptake is limited by HCP expertise which is
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dependent upon resources and protected time
for learning and development [15]. Whilst cur-
rent DIY APS users have high expertise in dia-
betes self-care, as numbers increase, HCPs may
be asked to support individuals who lack a
deeper understanding of the technology [16].
Many of theDIY components are available via
the NHS, although some DIY users operate out-
of-warranty pumps, increasing the risk of system
failure. HCPs need to advise that users should
operate the DIY system at their own risk but also
provide training in components provided by the
NHS [14]. HCPs are duty-bound to inform the
patients/carers about the intendeduseofmedical
products and the risk of harm from the use of
products in an unregulated, non-conventional
manner. There have been concerns about the
accuracy of the FreeStyle Libredevice for looping,
particularly if safe calibrationdoesnotoccur [17].
Around a third of DIY APS users are children
using systems built by parents or family mem-
bers [12]. HCPs working with children and
young people with diabetes will need to con-
sider safeguarding issues when discussing the
risk and benefits of DIY systems with patients
and families. However, for most families, using
this technology will be a decision taken in the
best interests of their child after extensive
research and consideration.
CONCLUSION
The use of DIY hybrid closed-loops systems
continues to grow in popularity with patients
and their families. It is vital that HCPs have
some understanding of these systems and are
able to discuss possible risks and benefits with
their patients and support them where this is
feasible.
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